Winter Park, Florida--(Newsfile Corp. - July 13, 2026) - Adia Med Inc. (OTCQB: ADIA) (formerly Adia Nutrition Inc.), focused on regenerative medicine, stem cell therapies, and biologics, today highlighted its rapid advancement and major milestones achieved since the January 2024 leadership transition.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/304722_adia_med_x_banner.jpg
On January 22, 2024, Larry Powalisz assumed the role of CEO and Director following a change of control, with Rebecca Miller appointed as CFO. Since the transition, Adia Med Inc. has been bootstrap funded by CEO Larry Powalisz as it implemented a new business strategy centered on regenerative healthcare. Adia Med Inc. has been reaching key milestones at a rapid pace, surpassing its expected timelines.
In mid-2024, the company acquired Biolete LLC and formed a strategic partnership with former WWE/TNA star Jeff Sciullo and Cement Factory LLC. It later secured an 18% equity stake in Cement Factory while divesting Biolete to sharpen its regenerative focus. The company also formed key subsidiaries, including Adia Med of Winter Park, LLC, and Adia Labs, LLC. Following these developments, the company successfully removed its shell company status, effective June 30, 2024.
By late 2024, Adia Med leased its flagship clinic at 1561 W. Fairbanks Avenue in Winter Park, Florida. Operations began in January 2025, with the first patients treated and revenue generated from medical procedures. Multiple medical directors were appointed in 2024 and 2025, including Dr. Evan Thomas, MD, PhD, as Medical Director. In May 2025, the company retired over 25 million improperly issued shares through a court settlement, strengthening its capital structure.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/304722_clinic_building_image.jpg
Throughout 2025, revenue grew substantially to $637,145 in the first nine months, driven primarily by biologics sales through Adia Labs and procedures at the Adia Med clinics. The company secured FDA registration for its biologics and filed a provisional patent. In late 2025, following promising results from earlier individual treatments, Adia Med began the process to obtain IRB approval for a clinical study focused on autism spectrum disorder (ASD). In December 2025, the Adia Med of Winter Park ASD research study for children ages 3-12 received IRB approval and was registered on ClinicalTrials.gov, with expansion plans underway. In 2025, the company was successfully uplisted to the OTCQB Venture Market, enhancing transparency and investor access.